MX390435B - Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. - Google Patents

Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20.

Info

Publication number
MX390435B
MX390435B MX2019004969A MX2019004969A MX390435B MX 390435 B MX390435 B MX 390435B MX 2019004969 A MX2019004969 A MX 2019004969A MX 2019004969 A MX2019004969 A MX 2019004969A MX 390435 B MX390435 B MX 390435B
Authority
MX
Mexico
Prior art keywords
exon
growth factor
factor receptor
epidermal growth
selective inhibitor
Prior art date
Application number
MX2019004969A
Other languages
English (en)
Other versions
MX2019004969A (es
Inventor
Kazutaka Miyadera
Shinichi Hasako
Yoshimi Aoyagi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2019004969A publication Critical patent/MX2019004969A/es
Publication of MX390435B publication Critical patent/MX390435B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describe un agente antitumor que comprende un compuesto seleccionado del grupo que consiste de Compuestos A hasta D descritos en la especificación, o una sal de los mismos, para tratar un paciente con tumor maligno que expresa EGFR que tiene la mutación de inserción de exón 20.
MX2019004969A 2016-10-31 2017-10-13 Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. MX390435B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016213072 2016-10-31
PCT/JP2017/037186 WO2018079310A1 (ja) 2016-10-31 2017-10-13 エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤

Publications (2)

Publication Number Publication Date
MX2019004969A MX2019004969A (es) 2019-09-18
MX390435B true MX390435B (es) 2025-03-20

Family

ID=62024991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004969A MX390435B (es) 2016-10-31 2017-10-13 Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20.

Country Status (22)

Country Link
US (2) US11857513B2 (es)
EP (1) EP3533449B1 (es)
JP (1) JP6896755B2 (es)
KR (1) KR102639585B1 (es)
CN (1) CN110191711B (es)
AU (1) AU2017350440B2 (es)
BR (1) BR112019008374A2 (es)
DK (1) DK3533449T3 (es)
ES (1) ES2955832T3 (es)
FI (1) FI3533449T3 (es)
HU (1) HUE063712T2 (es)
IL (1) IL266239B2 (es)
JO (1) JOP20190073A1 (es)
MX (1) MX390435B (es)
MY (1) MY199395A (es)
PH (1) PH12019500957A1 (es)
PL (1) PL3533449T3 (es)
PT (1) PT3533449T (es)
SG (1) SG11201903875QA (es)
TW (1) TWI774699B (es)
WO (1) WO2018079310A1 (es)
ZA (1) ZA201902629B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
ES3033635T3 (en) * 2018-12-28 2025-08-06 Taiho Pharmaceutical Co Ltd L718 and/or l792 mutant treatment-resistant egfr inhibitor for use in the treatment of cancer
WO2020166680A1 (ja) 2019-02-15 2020-08-20 大鵬薬品工業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－アミン誘導体
CN112574208B (zh) * 2019-09-29 2022-09-13 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
WO2022007841A1 (zh) * 2020-07-09 2022-01-13 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
TW202515577A (zh) * 2023-06-27 2025-04-16 日商大鵬藥品工業股份有限公司 患有具有ｅｇｆｒ畸變的非小細胞肺癌之個體的治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
RU2007138264A (ru) 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
EP2452940B1 (en) 2009-07-10 2014-12-17 Taiho Pharmaceutical Co., Ltd. Azabicyclo compound and salt thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2662357B1 (en) 2011-01-07 2016-08-03 Taiho Pharmaceutical Co., Ltd. Bicyclic compounds or salts thereof for use in the treatment of cancer
US9145414B2 (en) 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
RU2581039C1 (ru) * 2012-02-23 2016-04-10 Тайхо Фармасьютикал Ко., Лтд. Хинолилпирролпиримидильное конденсированное соединение или его соль
WO2014129596A1 (ja) 2013-02-22 2014-08-28 大鵬薬品工業株式会社 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物
EP3037424B1 (en) * 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
PE20170268A1 (es) 2014-06-19 2017-04-21 Ariad Pharma Inc Compuestos de heteroarilo para la inhibicion de cinasa
JP6583614B2 (ja) 2015-05-11 2019-10-02 大同特殊鋼株式会社 アーク炉の電極折損防止装置
JP7065103B2 (ja) 2017-09-01 2022-05-11 大鵬薬品工業株式会社 エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤

Also Published As

Publication number Publication date
MY199395A (en) 2023-10-25
AU2017350440A1 (en) 2019-05-16
US20190262345A1 (en) 2019-08-29
KR20190080901A (ko) 2019-07-08
CN110191711B (zh) 2022-09-23
EP3533449A1 (en) 2019-09-04
EP3533449B1 (en) 2023-07-12
PH12019500957A1 (en) 2019-08-05
ZA201902629B (en) 2023-12-20
AU2017350440B2 (en) 2023-01-12
TW201821079A (zh) 2018-06-16
EP3533449A4 (en) 2020-06-17
IL266239B2 (en) 2023-10-01
IL266239A (en) 2019-06-30
TWI774699B (zh) 2022-08-21
NZ752937A (en) 2025-08-29
SG11201903875QA (en) 2019-05-30
BR112019008374A2 (pt) 2019-10-01
MX2019004969A (es) 2019-09-18
IL266239B1 (en) 2023-06-01
JOP20190073A1 (ar) 2019-04-07
RU2019116780A3 (es) 2020-12-28
ES2955832T3 (es) 2023-12-07
RU2019116780A (ru) 2020-11-30
PT3533449T (pt) 2023-09-21
WO2018079310A1 (ja) 2018-05-03
CN110191711A (zh) 2019-08-30
CA3041015A1 (en) 2018-05-03
KR102639585B1 (ko) 2024-02-23
US11857513B2 (en) 2024-01-02
HUE063712T2 (hu) 2024-01-28
US20240148734A1 (en) 2024-05-09
DK3533449T3 (da) 2023-10-09
JP6896755B2 (ja) 2021-06-30
JPWO2018079310A1 (ja) 2019-09-12
FI3533449T3 (fi) 2023-09-15
PL3533449T3 (pl) 2023-11-20

Similar Documents

Publication Publication Date Title
MX390435B (es) Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2021003478A (es) Compuestos utiles como inhibidores de cinasa.
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX393599B (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
IL280158A (en) Methods of treating cancer with the PI3K inhibitor, GDC-0077
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
MY201673A (en) Polycyclic amide derivatives as cdk9 inhibitors
TN2019000211A1 (en) Antitumoral compounds
ZA201607488B (en) Compounds for treating brain cancer
EA201991884A2 (ru) Ингибиторы g12c kras
AU2018380132A8 (en) Tubulin inhibitors
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2023000191A (es) Metodos de fabricacion y uso de inhibidores de pde9.
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
MX2018008507A (es) Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).
IL288408A (en) Methods of treating urinary system cancers
MX388409B (es) Composiciones y metodos para tratar canceres.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2020013757A (es) Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo.